Nevro (NVRO) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Nevro Reports Second Quarter 2015 Financial Results
August 6, 2015 4:02 PM EDTMENLO PARK, Calif., Aug. 6, 2015 /PRNewswire/ --Â Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and six months ended June 30, 2015.
Recent Accomplishments & Highlights:
Achieved revenue of $11.4 million in the second quarter of 2015, an increase of 52% as reported and 81% on a constant currency basis over the same period of the prior year Received FDA approval for HF10 Spinal Cord Stimulation (SCS) therapy with superiority labeling and... More